Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure

Cardiovascular Drugs and Therapy

Volumn 14, Issue 1, 2000, Pages 77-82

  Tanimura, Mitsuhiro ^a   Mishima, Takayuki ^a   Steinberg, Mitchell I ^b   Borzak, Steven ^a   Goldstein, Sidney ^a   Sabbah, Hani N ^a,c  

^a Division of Cardiovascular Medicine   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Animal models; Congestive heart failure; Inotropic agents; Sodium channel; Ventricular function

Indexed keywords

DIGOXIN; DOBUTAMINE; LY 366634; SODIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DOSE TIME EFFECT RELATION; DRUG SAFETY; DRUG STRUCTURE; ECHOCARDIOGRAPHY; HEART CONTRACTION; HEART FAILURE; HEART LEFT VENTRICLE; HEART RATE; HEMODYNAMICS; INOTROPISM; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIOTONIC AGENTS; CHRONIC DISEASE; DIGOXIN; DISEASE MODELS, ANIMAL; DOBUTAMINE; DOGS; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; SODIUM CHANNELS; SYMPATHOMIMETICS; VENTRICULAR FUNCTION;

EID: 0034090339     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007899307128     Document Type: Article

References (37)

1. 1. Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: distinguishing hype from hope. J Am Coll Cardiol 1988;12:1299-1317.
2. 2. Rahimtoola SH. The pharmacologic treatment of chronic congestive heart failure. Circulation 1989;80:693-699.
3. 3. Erlemeier H-H, Kupper W, Bleifeld W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and the lack of tolerance. Cardiovasc Drugs Ther 1992;6:391-398.
4. 4. Chatterjee K. Phosphodiesterase inhibitors: alterations in systemic and coronary hemodynamics. Basic Res Cardiol 1989;84(Suppl. 1):213-224.
5. 5. Kanayama H, Ban M, Ogawa K, Satake T. Myocardial concentration of norepinephrine and cyclic AMP in ventricular fibrillation during acute myocardial ischemia. J Cardiovasc Pharmacol 1982;4:1018-1023.
6. 6. Lubbe WF, Podquweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992;19:1622-1633.
7. 7. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995;38:167-180.
8. 8. Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Proarrhythmic effects of intravenous vasopressors. Ann Pharmacother 1995;29:269-281.
9. 9. Baumgart D, Ehring T, Krajcar M, Skyschally A, Heusch G. Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: a comparison to its S-enantiomer BDF 9196, to its congener DPI 201-106, to norepinephrine, and to ouabain. Basic Res Cardiol 1994; 89:61-79.
10. 10. Raap A, Mest H-J, Stenzel W, Schloos J, Blechacz W. Investigation of the mechanism of the positive inotropic action of BDF 9148; comparison with DPI 201-106 and the enantiomers. J Cardiovasc Pharmacol 1997;29:164-173.
11. 11. Steinberg MI, McCall E, Mest H-J, Raap A, Wright T. Cardiac sodium channels as targets for new inotropic agents. Heart Failure Rev 1998;2:173-193.
12. 12. Buggisch D, Isenberg G, Ravens U, Scholtysik GJ. The role of sodium channels in the effect of the cardiotonic compound DPI 201-106 on contractility and membrane potentials in isolated mammalian heart preparation. Eur J Pharmacol 1985;118:303-311.
13. 13. Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1991.
14. 14. Raap A, Armah B, Hofferber E, Stenzel W, Schloos J, Blechacz W. BDF 9148: Comparison of action potential duration in vitro and prolongation of Q-T interval in anesthetized dogs (time course study) (abstract). Naunyn Schmiedebergs Arch Pharmacol 1991;344:R85.
15. 15. Rüegg PC, Nüesch E. The effect of a new inotropic agent, DPI 201-106, on systolic time intervals and the electrocardiogram in healthy subjects. Br J Clin Pharmacol 1987; 24:453-458.
16. 16. Algra A, Tijssen GJP, Roelandt JRTC, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991;83:1888-1894.
17. 17. Sabbah HN, Levine TB, Gheorghiade M, Kono T, Goldstein S. Hemodynamic response of a canine model of chronic heart failure to intravenous dobutamine, nitroprusside, enalaprilat and digoxin. Cardiovasc Drugs Ther 1993;7:349-356.
18. 18. Sabbah HN, Stein PD, Kono T, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-H1384.
19. 19. Sabbah HN, Shimoyama H, Kono T, et al. Effects of long term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994; 89:2852-2859.
20. 20. Hoey A, Amos GJ, Ravens U. Comparison of the action potential prolonging and positive inotropic action of DPI 201-106 and BDF 9148 in human ventricular myocardium. J Mol Cell Cardiol 1994;26:985-994.
21. + channel modulator BDF 9198 in human nonfailing and failing myocardium. J Cardiovasc Pharmacol 1998;31:684-689.
22. + -channel activators BDF 9148, BDF 9196 and BDF 9167 in human failing and nonfailing myocardium. J Pharmacol Exp Ther 1996; 276:1180-1188.
23. 2+ exchanger in failing human myocardium. Circulation 1996;94:992-1002.
24. 2+ exchanger in end-stage human heart failure. Circ Res 1994;75:443-453.
25. 25. Hoey A, Lehmkuhl A, Sadony V, Ravens U. Inotropic actions of BDF 9148 and DPI 201-106 and their enantiomers in guinea-pig, rat and human atria. Eur J Pharmacol 1993; 231:477-480.
26. + channel activation as a positive inotropic principle. J Cardiovasc Pharmacol 1989;14(Suppl. 3):S24-S29.
27. 27. Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-76.
28. 2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 1989;65:1141-1144.
29. + channel modulators, LY366634 and LY 368052, in isolated cardiac myocytes (abstract). J Heart Failure 1997;4:A270.
30. 30. Schwinger RHG, Böhm M, Müller-Ehmsen J, et al. Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart. Circulation 1993;88: 2267-2276.
31. 31. Borchard M, Ravens U. Intracellularly applied sodium mimics the effects of ouabain in single cardiac myocytes. Eur J Pharmacol 1986;131:269-272.
32. 32. Ravens U, Wettwer E, Pfeifer T, Himmel H, Armah B. Characterization of the effects of the new inotropic agent BDF 9148 in isolated papillary muscles and myocytes of the guinea-pig heart. Br J Pharmacol 1991;104:1019-1023.
33. 33. Hoey A, Amos GJ, Wettwer E, Ravens U. Differential effects of BDF 9148 and DPI 201-106 on action potential and contractility in rat and guinea pig myocardium. J Cardiovasc Pharmacol 1994;23:907-915.
34. 34. Levy MN. Role of calcium in arrhythmogenesis. Circulation 1989;80(Suppl IV):IV-23-IV-30.
35. 35. Scholtysik G, Salzman R, Gerber W. Interaction of DPI 201-106 with cardiac glucosides. J Cardiovasc Pharmacol 1989; 13:342-347.
36. 36. Rasch H, Iven H. Inotropic and electrophysiological effects of BDF 9148, a congener of DPI 201-106, in guinea pig atria and papillary muscles. Br J Pharmacol 1991;103: 1339-1345.
37. + -channel activators increase cardiac glyeoside in failing human myocardium. J Cardiovasc Pharmacol 1992;19:554-561.